Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 12/20 | 0.81 |
| ▸ | KMT2A | Q03164 | 12/20 | 0.81 |
| ▸ | CYP3A4 | P08684 | 12/20 | 0.81 |
| ▸ | KDM4E | B2RXH2 | 9/20 | 0.81 |
| ▸ | HSD17B10 | Q99714 | 8/20 | 0.81 |
| ▸ | MAPT | P10636 | 8/20 | 0.81 |
| ▸ | ALOX15 | P16050 | 6/20 | 0.81 |
| ▸ | CASP1 | P29466 | 4/20 | 0.81 |
| ▸ | CASP7 | P55210 | 4/20 | 0.81 |
| ▸ | CYP2C9 | P11712 | 8/20 | 0.78 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.78 |
| ▸ | HPGD | P15428 | 7/20 | 0.78 |
| ▸ | CYP2C19 | P33261 | 5/20 | 0.78 |
| ▸ | CYP2D6 | P10635 | 4/20 | 0.78 |
| ▸ | DHFR | P00374 | 1/20 | 0.78 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.78 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.78 |
| ▸ | MAPK1 | P28482 | 7/20 | 0.75 |
| ▸ | TP53 | P04637 | 6/20 | 0.75 |
| ▸ | RECQL | P46063 | 3/20 | 0.72 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31675772 | 1.00 | MEN1 (0.81) | MEN1KMT2ACYP3A4KDM4EHSD17B10 | |
| Resokaempferol SCHEMBL4728192 | 0.91 | MEN1 (0.82) | MEN1KMT2ACYP3A4KDM4EHSD17B10 | |
| 3,7-Dihydroxyflavone SCHEMBL29625323 | 0.89 | CYP3A4 (1.00) | MEN1KMT2ACYP3A4KDM4EHSD17B10 | |
| 3,7-Dihydroxyflavone SCHEMBL2396684 | 0.89 | CYP3A4 (1.00) | MEN1KMT2ACYP3A4KDM4EHSD17B10 | |
| SCHEMBL17356386 | 0.89 | MAPT (0.71) | MEN1KMT2ACYP3A4KDM4EHSD17B10 | |
| SCHEMBL1628821 | 0.88 | DHFR (1.00) | MEN1KMT2ACYP3A4KDM4EHSD17B10 | |
| SCHEMBL345657 | 0.88 | MEN1 (1.00) | MEN1KMT2ACYP3A4KDM4EHSD17B10 | |
| SCHEMBL25238273 | 0.87 | CYP1A2 (0.76) | MEN1KMT2ACYP3A4KDM4EHSD17B10 | |
| Resokaempferol SCHEMBL30873045 | 0.86 | MEN1 (1.00) | MEN1KMT2ACYP3A4KDM4EHSD17B10 | |
| Resokaempferol SCHEMBL344710 | 0.86 | MEN1 (1.00) | MEN1KMT2ACYP3A4KDM4EHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7897637-B2 | Methods of using flavonoids to enhance memory | THE SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) | 2011-03-01 | — | — | US | claimed |
| WO-2008011538-A2 | METHODS OF USING FLAVONOIDS TO ENHANCE MEMORY | THE SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) | 2008-01-24 | — | — | WO | claimed |
| US-20080021096-A1 | METHODS OF USING FLAVONOIDS TO ENHANCE MEMORY | THE SALK INSTITUTE FOR BIOLOGICAL STUDIES | 2008-01-24 | — | — | US | claimed |
| WO-2007083904-A1 | C-KIT ACTIVATION INHIBITOR, SKIN WHITENING COMPOUND AND COMPOSITION FOR SKIN WHITENING CONTAINING THE SAME | LG HOUSEHOLD & HEALTH CARE LTD. (KR) | 2007-07-26 | — | — | WO | claimed |
| US-20250263774-A1 | DISCOVERING NEW XENOBIOTIC SUBSTRATES OF AN UDP-GLYCOSYLTRANSFERASE WITH A HIGH-THROUGHPUT METHOD | UNIV NORTH TEXAS (US) | 2025-08-21 | — | — | US | disclosed |
| US-20220387542-A1 | PROTECTIVE EFFECTS OF OIL PALM COMPOSITION ON ALZHEIMER'S DISEASE | MALAYSIAN PALM OIL BOARD (MY) | 2022-12-08 | — | — | US | disclosed |
| US-11517607-B2 | Protective effects of oil palm composition on Alzheimer's disease | MALAYSIAN PALM OIL BOARD (MY) | 2022-12-06 | — | — | US | disclosed |
| US-20220193087-A1 | COMBINATION THERAPIES FOR THE TREATMENT OF ALZHEIMER'S DISEASE AND RELATED DISORDERS | THE GENERAL HOSPITAL CORPORATION | 2022-06-23 | — | — | US | disclosed |
| US-11110097-B2 | Combination therapies for the treatment of alzheimer's disease and related disorders | THE GENERAL HOSPITAL CORPORATION (US) | 2021-09-07 | — | — | US | disclosed |
| EP-3057437-B1 | PROTECTIVE EFFECTS OF OIL PALM COMPOSITION ON ALZHEIMER'S DISEASE | MALAYSIAN PALM OIL BOARD (MY) | 2020-10-07 | — | — | EP | disclosed |
| US-20200085903-A1 | Protective Effects of Oil Palm Composition on Alzheimer's Disease | MALAYSIAN PALM OIL BOARD (MY) | 2020-03-19 | — | — | US | disclosed |
| US-20200078366-A1 | COMBINATION THERAPIES FOR THE TREATMENT OF ALZHEIMER'S DISEASE AND RELATED DISORDERS | THE GENERAL HOSPITAL CORPORATION | 2020-03-12 | — | — | US | disclosed |
| WO-2008011538-A2 | METHODS OF USING FLAVONOIDS TO ENHANCE MEMORY | THE SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) | 2008-01-24 | — | — | WO | disclosed |
| WO-2008011538-A2 | METHODS OF USING FLAVONOIDS TO ENHANCE MEMORY | THE SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) | 2008-01-24 | — | — | WO | disclosed |
| US-20080021096-A1 | METHODS OF USING FLAVONOIDS TO ENHANCE MEMORY | THE SALK INSTITUTE FOR BIOLOGICAL STUDIES | 2008-01-24 | — | — | US | disclosed |
| US-20070254859-A1 | Compounds exhibiting efflux inhibitor activity and composition and uses thereof | EASTMAN CHEMICAL COMPANY | 2007-11-01 | — | — | US | disclosed |
| WO-2007115181-A2 | COMPOUNDS EXHIBITING EFFLUX INHIBITOR ACTIVITY AND COMPOSITIONS AND USES THEREOF | EASTMAN CHEMICAL COMPANY (US) | 2007-10-11 | — | — | WO | disclosed |
| WO-2007083904-A1 | C-KIT ACTIVATION INHIBITOR, SKIN WHITENING COMPOUND AND COMPOSITION FOR SKIN WHITENING CONTAINING THE SAME | LG HOUSEHOLD & HEALTH CARE LTD. (KR) | 2007-07-26 | — | — | WO | disclosed |
| WO-2007083904-A1 | C-KIT ACTIVATION INHIBITOR, SKIN WHITENING COMPOUND AND COMPOSITION FOR SKIN WHITENING CONTAINING THE SAME | LG HOUSEHOLD & HEALTH CARE LTD. (KR) | 2007-07-26 | — | — | WO | disclosed |
| WO-2006030322-A2 | USE OF FLA VONE/FLA VANONE DERIVATIVES FN THE TREATMENT OR PREVENTION OF RESPIRATORY CONDITIONS | UNIVERSITY OF MANITOBA (CA) | 2006-03-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200078366-A1 | COMBINATION THERAPIES FOR THE TREATMENT OF ALZHEIMER'S DISEASE AND RELATED DISORDERS | APP, SNCA, MAPT | MEN1 3532/4885KMT2A 3135/4885CYP3A4 4830/4885 |
| US-20070254859-A1 | Compounds exhibiting efflux inhibitor activity and composition and uses thereof | ABCC4, NCOA4, NR4A3 | MEN1 4281/4885KMT2A 4362/4885CYP3A4 17/4885 |
| US-11110097-B2 | Combination therapies for the treatment of alzheimer's disease and related disorders | APP, SNCA, MAPT | MEN1 3532/4885KMT2A 3135/4885CYP3A4 4830/4885 |
| US-20080021096-A1 | METHODS OF USING FLAVONOIDS TO ENHANCE MEMORY | FOS, CREBBP, CREB1 | MEN1 3520/4885KMT2A 1152/4885CYP3A4 4468/4885 |
| US-20220193087-A1 | COMBINATION THERAPIES FOR THE TREATMENT OF ALZHEIMER'S DISEASE AND RELATED DISORDERS | APP, SNCA, MAPT | MEN1 3532/4885KMT2A 3135/4885CYP3A4 4830/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.